

For Immediate Release

Otsuka Pharmaceutical Factory and Mitsui enter into IV solutions business in India

Tokyo, December 7, 2012—Otsuka Pharmaceutical Factory, Inc. ("OPF"), Mitsui & Co., Ltd. ("Mitsui"), and Claris Lifesciences Limited ("Claris") reached an agreement today to establish a joint venture company specialized in IV solutions business in India.

Claris, listed on Mumbai Stock Exchange, is one of the leading manufacturers and distributors of IV solutions and generic pharmaceuticals in India. OPF and Mitsui will invest approximately 10.5 billion INR (approximately 16 billion JPY) in the new company ("Claris Otsuka" – tentative name) and the equity stake for each company will be; OPF: 60%, Mitsui: 20%, and Claris: 20%.

The IV solutions market in India is expected to benefit from demand expansion driven by its economic growth and improvement in middle class incomes, combined with the development of insurance systems and the increase in the number of medical institutions. In the future, India is expected to become one of the world's largest pharmaceutical markets. OPF, the leading company of IV solutions in Japan, and Mitsui, a company that possesses established networks all over the world, will join forces to meet the increasing demand for IV solutions in India as well as in the emerging countries through Claris' existing distribution network in India and other 52 countries.

OPF has identified India as one of the priority countries for its overseas expansion. By providing high quality basic solutions, and by introducing new value-added clinical nutrition products to India in the future, OPF will contribute to the advancement of medical care in India. Under the Otsuka Group's corporate philosophy, "Otsuka-people creating new products for better health worldwide," OPF will contribute to the betterment of the people of India as well as people around the world.

Mitsui has determined that the medical and healthcare fields as key areas of businesses, and in anticipation of expanding demand for pharmaceutical products in the emerging countries, is reinforcing its initiatives. Through the joint venture, with IV business



partners, OPF and Claris, Mitsui aims to contribute to increase the quality of medical care in India and in other emerging countries.

Company Profiles

New Joint Venture Company

Company Name	:	Claris Otsuka Limited (tentative)
Headquarters	:	Ahmadabad, Gujarat, India
Representative	:	Bharat Shah, CEO
Establishment Date	:	Planned for 2013
Number of	:	Approximately 700
Employees		
Capital	:	10.524 billion INR (approximately 16 billion JPY)
Ownership	:	OPF : 60%, Claris:20%, Mitsui : 20%
Scope of Business	:	Manufacture and distribution of basic solution and clinical
_		nutrition products
Business Area	:	India and 52 countries worldwide

Claris LifeSciences Limited

Headquarters	:	Ahmedabad, Gujarat, India
Representative	:	Arjun Handa, Managing Director & CEO
Establishment Date	:	1999
Capital	:	638 million INR (approximately 970 million JPY)
Number of	:	1,250
Employees		
Scope of Business	:	Manufacture and distribution of pharmaceutical and
_		nutrition products